As pharmaceutical companies stepped back from developing new drugs for neurological conditions, venture capitalists took a big step forward.
Venture investors have poured more than $500 million into early-stage neurology startups this year, according to a recent health care venture capital report from Silicon Valley Bank — more than six times as much money that was invested in the same over the first six months of last year.
About the Author Reprints
